10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes, New England Journal of Medicine, vol.359, issue.15, pp.1577-1589, 2008. ,
DOI : 10.1056/NEJMoa0806470
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy, New England Journal of Medicine, vol.355, issue.23, pp.2477-2480, 2006. ,
DOI : 10.1056/NEJMoa066224
Incretin Effects of Increasing Glucose Loads in Man Calculated from Venous Insulin and C-Peptide Responses*, The Journal of Clinical Endocrinology & Metabolism, vol.63, issue.2, pp.492-498, 1986. ,
DOI : 10.1210/jcem-63-2-492
Incretins, insulin secretion and Type 2 diabetes mellitus, Diabetologia, vol.47, issue.3, pp.357-366, 2004. ,
DOI : 10.1007/s00125-004-1342-6
Glucagon-like peptide-1(7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns, Journal of Endocrinology, vol.138, issue.1, pp.159-166, 1993. ,
DOI : 10.1677/joe.0.1380159
Exon duplication and divergence in the human preproglucagon gene, Nature, vol.143, issue.5924, pp.368-371, 1983. ,
DOI : 10.1038/304368a0
Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas*, Endocrinology, vol.119, issue.4, pp.1467-1475, 1986. ,
DOI : 10.1210/endo-119-4-1467
GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN, The Lancet, vol.330, issue.8571, pp.1300-1304, 1987. ,
DOI : 10.1016/S0140-6736(87)91194-9
Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line., Proceedings of the National Academy of Sciences, vol.84, issue.10, pp.3434-3438, 1987. ,
DOI : 10.1073/pnas.84.10.3434
Biology of Incretins: GLP-1 and GIP, Gastroenterology, vol.132, issue.6, pp.2131-2157, 2007. ,
DOI : 10.1053/j.gastro.2007.03.054
Glucagonlike Peptide I (7-37) Actions on Endocrine Pancreas, Diabetes, vol.38, issue.3, pp.338-342, 1989. ,
DOI : 10.2337/diab.38.3.338
Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling, Diabetes, vol.47, issue.4, pp.632-639, 1998. ,
DOI : 10.2337/diabetes.47.4.632
Glucose-Dependent Insulinotropic Polypeptide Enhances Adipocyte Development and Glucose Uptake in Part Through Akt Activation, Gastroenterology, vol.133, issue.6, pp.1796-1805, 2007. ,
DOI : 10.1053/j.gastro.2007.09.005
GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet, AJP: Endocrinology and Metabolism, vol.293, issue.6, pp.1746-1755, 2007. ,
DOI : 10.1152/ajpendo.00460.2007
Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice, Proceedings of the National Academy of Sciences, vol.96, issue.26, pp.14843-14847, 1999. ,
DOI : 10.1073/pnas.96.26.14843
Inhibition of gastric inhibitory polypeptide signaling prevents obesity, Nature Medicine, vol.8, issue.7, pp.738-742, 2002. ,
DOI : 10.1038/nm727
Double Incretin Receptor Knockout (DIRKO) Mice Reveal an Essential Role for the Enteroinsular Axis in Transducing the Glucoregulatory Actions of DPP-IV Inhibitors, Diabetes, vol.53, issue.5, pp.1326-1335, 2004. ,
DOI : 10.2337/diabetes.53.5.1326
Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes, Diabetologia, vol.24, issue.Suppl 82, pp.46-52, 1986. ,
DOI : 10.1007/BF02427280
Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients, Diabetes, vol.50, issue.3, pp.609-613, 2001. ,
DOI : 10.2337/diabetes.50.3.609
Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired ??-Cell Function?, Diabetes, vol.59, issue.5, pp.1117-1125, 2010. ,
DOI : 10.2337/db09-1899
Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients, The Journal of Clinical Endocrinology & Metabolism, vol.86, issue.8, pp.3717-3723, 2001. ,
DOI : 10.1210/jcem.86.8.7750
Impaired Incretin Response After a Mixed Meal Is Associated With Insulin Resistance in Nondiabetic Men, Diabetes Care, vol.24, issue.9, pp.1640-1645, 2001. ,
DOI : 10.2337/diacare.24.9.1640
Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance, Diabetes, vol.57, issue.3, pp.678-687, 2008. ,
DOI : 10.2337/db07-1124
Attenuated GLP-1 secretion in obesity: cause or consequence?, Gut, vol.38, issue.6, pp.916-919, 1996. ,
DOI : 10.1136/gut.38.6.916
Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients, Diabetes, vol.57, issue.5, pp.1340-1348, 2008. ,
DOI : 10.2337/db07-1315
Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects, Diabetes, vol.44, issue.9, pp.1126-1131, 1995. ,
DOI : 10.2337/diab.44.9.1126
Degradation of Endogenous and Exogenous Gastric Inhibitory Polypeptide in Healthy and in Type 2 Diabetic Subjects as Revealed Using a New Assay for the Intact Peptide, Journal of Clinical Endocrinology & Metabolism, vol.85, issue.10, pp.3575-3581, 2000. ,
DOI : 10.1210/jc.85.10.3575
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance, Proceedings of the National Academy of Sciences, vol.100, issue.11, pp.6825-6830, 2003. ,
DOI : 10.1073/pnas.0631828100
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC164531
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26, Proceedings of the National Academy of Sciences, vol.97, issue.12, pp.6874-6879, 2000. ,
DOI : 10.1073/pnas.120069197
Long-Term Treatment With the Dipeptidyl Peptidase IV Inhibitor P32/98 Causes Sustained Improvements in Glucose Tolerance, Insulin Sensitivity, Hyperinsulinemia, and ??-Cell Glucose Responsiveness in VDF (fa/fa) Zucker Rats, Diabetes, vol.51, issue.4, pp.943-950, 2002. ,
DOI : 10.2337/diabetes.51.4.943
Dipeptidyl Peptidase IV Inhibitor Treatment Stimulates ??-Cell Survival and Islet Neogenesis in Streptozotocin-Induced Diabetic Rats, Diabetes, vol.52, issue.3, pp.741-750, 2003. ,
DOI : 10.2337/diabetes.52.3.741
Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide, Diabetes, vol.47, issue.8, pp.1253-1258, 1998. ,
DOI : 10.2337/diab.47.8.1253
Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study mice with beta-cell-specific overexpression of human islet amyloid polypeptide, Diabetes Regul.Pept, vol.51, issue.143, pp.2677-268397, 2002. ,
Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not, Diabetes, vol.56, issue.1, pp.8-15, 2007. ,
DOI : 10.2337/db06-0565
Inhibition of Dipeptidyl Peptidase IV With Sitagliptin (MK0431) Prolongs Islet Graft Survival in Streptozotocin-Induced Diabetic Mice, Diabetes, vol.57, issue.5, pp.1331-1339, 2008. ,
DOI : 10.2337/db07-1639
Differential Importance of Glucose-Dependent Insulinotropic Polypeptide vs Glucagon-Like Peptide 1 Receptor Signaling for Beta Cell Survival in Mice, Gastroenterology, vol.137, issue.6, pp.2146-2157, 2009. ,
DOI : 10.1053/j.gastro.2009.09.004
Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes, European Journal of Pharmacology, vol.623, issue.1-3, pp.148-154, 2009. ,
DOI : 10.1016/j.ejphar.2009.09.027
Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic ??-Cell Mass and Function in a Rodent Model of Type 2 Diabetes, Diabetes, vol.55, issue.6, pp.1695-1704, 2006. ,
DOI : 10.2337/db05-1602
Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes, Diabetologia, vol.53, issue.Suppl 2, pp.616-620, 2005. ,
DOI : 10.1007/s00125-005-1707-5
Incretin Receptors for Glucagon-Like Peptide 1 and Glucose-Dependent Insulinotropic Polypeptide Are Essential for the Sustained Metabolic Actions of Vildagliptin in Mice, Diabetes, vol.56, issue.12, pp.3006-3013, 2007. ,
DOI : 10.2337/db07-0697
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses, Clinical Pharmacology & Therapeutics, vol.78, issue.6, pp.675-688, 2005. ,
DOI : 10.1016/j.clpt.2005.09.002
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers, Clinical Therapeutics, vol.28, issue.1, pp.55-72, 2006. ,
DOI : 10.1016/j.clinthera.2006.01.015
Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP-4 Inhibitor Sitagliptin in Middle-Aged Obese Subjects, The Journal of Clinical Pharmacology, vol.379, issue.Suppl 2, pp.876-886, 2006. ,
DOI : 10.1177/0091270006289850
)-pyrrolidine:?? A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties, Journal of Medicinal Chemistry, vol.46, issue.13, pp.2774-2789, 2003. ,
DOI : 10.1021/jm030091l
Pharmacokinetics and Pharmacodynamics of Vildagliptin??in??Patients?? with Type??2??Diabetes??Mellitus, Clinical Pharmacokinetics, vol.283, issue.8, pp.577-588, 2007. ,
DOI : 10.2165/00003088-200746070-00003
Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT, The Journal of Clinical Pharmacology, vol.91, issue.suppl 1, pp.633-641, 2007. ,
DOI : 10.1177/0091270006299137
Discovery and Preclinical Profile of Saxagliptin (BMS-477118):?? A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes, Journal of Medicinal Chemistry, vol.48, issue.15, pp.5025-5037, 2005. ,
DOI : 10.1021/jm050261p
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes, Clinical Therapeutics, vol.30, issue.3, pp.499-512, 2008. ,
DOI : 10.1016/j.clinthera.2008.03.004
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers, The Journal of Clinical Pharmacology, vol.78, issue.6, pp.1171-1178, 2008. ,
DOI : 10.1177/0091270008323753
Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients, Diabetes, Obesity and Metabolism, vol.61, issue.8, pp.786-794, 2009. ,
DOI : 10.1111/j.1463-1326.2009.01046.x
Effect of Renal Insufficiency on the Pharmacokinetics of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Diabetes Care, vol.30, issue.7, pp.1862-1864, 2007. ,
DOI : 10.2337/dc06-2545
Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [14C]Sitagliptin in Humans, Drug Metabolism and Disposition, vol.35, issue.4, pp.533-538, 2007. ,
DOI : 10.1124/dmd.106.013136
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency, Diabetes, Obesity and Metabolism, vol.10, issue.7, pp.545-555, 2008. ,
DOI : 10.1111/j.1463-1326.2006.00704.x
Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin*, Diabetes, Obesity and Metabolism, vol.13, issue.Suppl. 1, pp.939-946, 2011. ,
DOI : 10.1111/j.1463-1326.2011.01458.x
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin ??? diabetes control and potential adverse events, Best Practice & Research Clinical Endocrinology & Metabolism, vol.23, issue.4, pp.487-498, 2009. ,
DOI : 10.1016/j.beem.2009.03.003
Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes: Potential Importance of Selectivity Over Dipeptidyl Peptidases 8 and 9, Diabetes, vol.54, issue.10, pp.2988-2994, 2005. ,
DOI : 10.2337/diabetes.54.10.2988
Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited, Diabetes, Obesity and Metabolism, vol.54, issue.11, pp.1057-1061, 2008. ,
DOI : 10.1111/j.1463-1326.2008.00860.x
Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes, Diabetes Care, vol.29, issue.12, pp.2632-2637, 2006. ,
DOI : 10.2337/dc06-0703
Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes, Diabetes Care, vol.30, issue.8, pp.1979-1987, 2007. ,
DOI : 10.2337/dc07-0627
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone, Diabetes Care, vol.29, issue.12, pp.2638-2643, 2006. ,
DOI : 10.2337/dc06-0706
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, Clinical Therapeutics, vol.28, issue.10, pp.1556-1568, 2006. ,
DOI : 10.1016/j.clinthera.2006.10.007
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial, Diabetes, Obesity and Metabolism, vol.118, issue.2, pp.194-205, 2007. ,
DOI : 10.1016/j.clinthera.2006.10.007
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study, International Journal of Clinical Practice, vol.287, issue.5, pp.562-576, 2010. ,
DOI : 10.1111/j.1742-1241.2010.02353.x
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial, The Lancet, vol.375, issue.9724, pp.1447-1456, 2010. ,
DOI : 10.1016/S0140-6736(10)60307-8
Efficacy and tolerability of vildagliptin monotherapy in drug-na??ve patients with type 2 diabetes, Diabetes Research and Clinical Practice, vol.76, issue.1, pp.132-138, 2007. ,
DOI : 10.1016/j.diabres.2006.12.009
Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2 Diabetes Inadequately Controlled With Metformin, Diabetes Care, vol.30, issue.4, pp.890-895, 2007. ,
DOI : 10.2337/dc06-1732
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy, Diabetes, Obesity and Metabolism, vol.30, issue.2, pp.157-166, 2009. ,
DOI : 10.1111/j.1463-1326.2008.00994.x
Effect of linagliptin monotherapy on glycaemic control and markers of ??-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial, Diabetes, Obesity and Metabolism, vol.55, issue.(Suppl. 1), pp.258-267, 2011. ,
DOI : 10.1111/j.1463-1326.2010.01350.x
Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study, Diabetes, Obesity and Metabolism, vol.63, issue.Suppl. 1, pp.65-74, 2011. ,
DOI : 10.1111/j.1463-1326.2010.01326.x
Safety and Efficacy of Linagliptin in Type 2 Diabetes Patients with Severe Renal Impairment, Diabetes, vol.60, p.114, 2011. ,
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study, Diabetes Care, vol.31, issue.12, pp.2315-2317, 2008. ,
DOI : 10.2337/dc08-1035
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study, International Journal of Clinical Practice, vol.39, issue.1, pp.46-55, 2009. ,
DOI : 10.1111/j.1742-1241.2008.01933.x
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy, Diabetes, Obesity and Metabolism, vol.10, issue.Suppl. 1, pp.167-176, 2009. ,
DOI : 10.1111/j.1463-1326.2008.01016.x
without causing weight gain or increased hypoglycaemia, Diabetes, Obesity and Metabolism, vol.321, issue.12, pp.1145-1152, 2009. ,
DOI : 10.1111/j.1463-1326.2009.01124.x
Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes, Diabetes, Obesity and Metabolism, vol.445, issue.5, pp.376-386, 2008. ,
DOI : 10.1111/j.1463-1326.2005.00539.x
Effect of saxagliptin monotherapy in treatment-na??ve patients with type 2 diabetes, Current Medical Research and Opinion, vol.25, issue.10, pp.2401-2411, 2009. ,
DOI : 10.1185/03007990903178735
The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone, Diabetes Care, vol.32, issue.9, pp.1649-1655, 2009. ,
DOI : 10.2337/dc08-1984
Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.12, pp.4810-4819, 2009. ,
DOI : 10.1210/jc.2009-0550
Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial, International Journal of Clinical Practice, vol.41, issue.Suppl. 1, pp.1395-1406, 2009. ,
DOI : 10.1111/j.1742-1241.2009.02143.x
Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment, Diabetes, Obesity and Metabolism, vol.12, issue.3 Suppl. 3, pp.523-532, 2011. ,
DOI : 10.1111/j.1463-1326.2011.01382.x
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus, Diabetes/Metabolism Research and Reviews, vol.11, issue.7, pp.540-549, 2010. ,
DOI : 10.1002/dmrr.1114
Behavioral characterization of CD26 deficient mice in animal tests of anxiety and antidepressant-like activity, Behavioural Brain Research, vol.171, issue.2, pp.279-285, 2006. ,
DOI : 10.1016/j.bbr.2006.04.003
URL : https://hal.archives-ouvertes.fr/hal-00135369
Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen, European Journal of Immunology, vol.33, issue.6, pp.1519-1527, 2003. ,
DOI : 10.1002/eji.200323469
Dipeptidyl Peptidase IV Inhibition With MK0431 Improves Islet Graft Survival in Diabetic NOD Mice Partially via T-Cell Modulation, Diabetes, vol.58, issue.3, pp.641-651, 2009. ,
DOI : 10.2337/db08-1101
DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes, Atherosclerosis, vol.213, issue.2, pp.429-435, 2010. ,
DOI : 10.1016/j.atherosclerosis.2010.08.064
Modulation of Hematopoietic Stem Cell Homing and Engraftment by CD26, Science, vol.305, issue.5686, pp.1000-1003, 2004. ,
DOI : 10.1126/science.1097071
Incretin-Based Therapies: Viewpoints on the way to consensus, Diabetes Care, vol.32, issue.suppl_2, pp.223-231, 2009. ,
DOI : 10.2337/dc09-S315
Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion, Circulation, vol.109, issue.8, pp.962-965, 2004. ,
DOI : 10.1161/01.CIR.0000120505.91348.58
Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4, Diabetes, vol.59, issue.4, pp.1030-1037, 2010. ,
DOI : 10.2337/db09-1694
Cardiac Function in Mice Lacking the Glucagon-Like Peptide-1 Receptor, Endocrinology, vol.144, issue.6, pp.2242-2252, 2003. ,
DOI : 10.1210/en.2003-0007
Glucagon-Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients With Chronic Heart Failure, Journal of Cardiac Failure, vol.12, issue.9, pp.694-699, 2006. ,
DOI : 10.1016/j.cardfail.2006.08.211
Effect of Glucagon-Like Peptide-1 (GLP-1) on Glycemic Control and Left Ventricular Function in Patients Undergoing Coronary Artery Bypass Grafting, The American Journal of Cardiology, vol.100, issue.5, pp.824-829, 2007. ,
DOI : 10.1016/j.amjcard.2007.05.022
Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database, Diabetes Care, vol.34, issue.1, pp.90-95, 2011. ,
DOI : 10.2337/dc10-1393
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure, AJP: Heart and Circulatory Physiology, vol.298, issue.3, pp.1096-1102, 2010. ,
DOI : 10.1152/ajpheart.00930.2009
DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease, Circulation: Cardiovascular Imaging, vol.3, issue.2, pp.195-201, 2010. ,
DOI : 10.1161/CIRCIMAGING.109.899377
Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice, Diabetes, vol.59, issue.4, pp.1063-1073, 2010. ,
DOI : 10.2337/db09-0955
A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes, Postgraduate Medicine, vol.361, issue.7, pp.16-27, 2010. ,
DOI : 10.1113/jphysiol.2009.176461
Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials, Nutrition, Metabolism and Cardiovascular Diseases, vol.20, issue.4, pp.224-235, 2010. ,
DOI : 10.1016/j.numecd.2009.03.015
Rationale and Design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) ADA, 2009. ,
Rationale and Design of the CAROLINA Trial: An Active Comparator CARdiOvascular Outcome ,
EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE), American Heart Journal, vol.162, issue.4, pp.620-626, 2011. ,
DOI : 10.1016/j.ahj.2011.08.004